| Literature DB >> 24917578 |
Daniel Beiroa1, Monica Imbernon1, Rosalía Gallego2, Ana Senra3, Daniel Herranz4, Francesc Villarroya5, Manuel Serrano4, Johan Fernø6, Javier Salvador7, Javier Escalada7, Carlos Dieguez1, Miguel Lopez1, Gema Frühbeck7, Ruben Nogueiras8.
Abstract
GLP-1 receptor (GLP-1R) is widely located throughout the brain, but the precise molecular mechanisms mediating the actions of GLP-1 and its long-acting analogs on adipose tissue as well as the brain areas responsible for these interactions remain largely unknown. We found that central injection of a clinically used GLP-1R agonist, liraglutide, in mice stimulates brown adipose tissue (BAT) thermogenesis and adipocyte browning independent of nutrient intake. The mechanism controlling these actions is located in the hypothalamic ventromedial nucleus (VMH), and the activation of AMPK in this area is sufficient to blunt both central liraglutide-induced thermogenesis and adipocyte browning. The decreased body weight caused by the central injection of liraglutide in other hypothalamic sites was sufficiently explained by the suppression of food intake. In a longitudinal study involving obese type 2 diabetic patients treated for 1 year with GLP-1R agonists, both exenatide and liraglutide increased energy expenditure. Although the results do not exclude the possibility that extrahypothalamic areas are also modulating the effects of GLP-1R agonists, the data indicate that long-acting GLP-1R agonists influence body weight by regulating either food intake or energy expenditure through various hypothalamic sites and that these mechanisms might be clinically relevant.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24917578 DOI: 10.2337/db14-0302
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461